GLP-1 medications are temperature-sensitive biologics
As noted above, mTOR signaling has emerged as a key control point for B cell functions 35
Hygum K, Starup-Linde J, Langdahl BL
Given their wide-ranging benefits, its no surprise that the use of GLP-1s has skyrocketed, with over 1.1 million patients prescribed between 2018 and 2024
Nicola Magrini, Unit head for Innovation, Evidence synthesis and Clinical research, University Hospital, Bologna, Italy, Co-Chair of the Guidelines Development Group Comments: GLP-1 and inclusion in the essential medicine Mr Deus Mubangizi, Director, Medicines and Health Products Policies and Standards Department, WHO Panel discussion Ms Jeanette Hunter General Primary Health Care at the National Department of Health (NDoH) of South Africa, and Co-Chair of the Guidelines Development Group